Novo Nordisk A/S establishes new Gulf office in Dubai Healthcare City

Chief Sales & Marketing Officer of DHCC, Omar Moawiyah Al Shunnar said, "We are extremely pleased to welcome Novo Nordisk to Dubai Healthcare City. Novo Nordisk is a world leading healthcare company that is globally reputed for diabetes care. Their presence at DHCC will provide access to seekers of diabetes care from all over the region at world-class quality and standards."

Explaining the choice of DHCC, Mads Bo Larsen, general manager for Novo Nordisk's Gulf Regional Office, said: "We will move into the new facility at Dubai Healthcare City towards the end of April. This will be a management office for the Gulf operations. The principal reasons for establishing the new entity in DHCC include the vision and mission of DHCC, the synergy created by our common commitment to healthcare excellence in the region, and the free zone incentives for foreign investment."

Novo Nordisk has the broadest diabetes product portfolio in the industry and a strong position in other areas including haemostasis management, growth disorders and hormone replacement therapy.

Mr Costas Piliounis, Novo Nordisk's vice president of North Africa & Gulf said, "We are proud to be associated with Dubai Healthcare City and look forward to working in cooperation to expand our commitment in the fields of diabetes care and haemostasis management in the region."

Al Shunnar pointed out that this is an important partnership as it reflects the trust of international medical establishments in the UAE and its international standing as a regional centre of excellence for healthcare services.